Frontiers in Neurology (Feb 2024)

Optimization of sensitivity and specificity of a biomarker-based blood test (LVOCheck-Opti): A protocol for a multicenter prospective observational study of patients suspected of having a stroke

  • Maximilian Kaffes,
  • Maximilian Kaffes,
  • Fulvio Bondi,
  • Frederik Geisler,
  • Ulrike Grittner,
  • Lisa Haacke,
  • Thomas Ihl,
  • Thomas Ihl,
  • Maren Lorenz,
  • Marc S. Schehadat,
  • Eugen Schwabauer,
  • Matthias Wendt,
  • Martina Zuber,
  • Dorothee Kübler-Weller,
  • Irina Lorenz-Meyer,
  • Irina Lorenz-Meyer,
  • Jean-Charles Sanchez,
  • Joan Montaner,
  • Joan Montaner,
  • Joan Montaner,
  • Heinrich J. Audebert,
  • Heinrich J. Audebert,
  • Joachim E. Weber,
  • Joachim E. Weber,
  • Joachim E. Weber,
  • Joachim E. Weber

DOI
https://doi.org/10.3389/fneur.2023.1327348
Journal volume & issue
Vol. 14

Abstract

Read online

IntroductionAcute ischemic stroke (AIS) is a time-critical medical emergency. For patients with large-vessel occlusions (LVO), mechanical thrombectomy (MT) is the gold-standard treatment. Mobile Stroke Units (MSUs) provide on-site diagnostic capabilities via computed tomography (CT) and have been shown to improve functional outcomes in stroke patients, but are cost-efficient only in urban areas. Blood biomarkers have recently emerged as possible alternative to cerebral imaging for LVO diagnosis. Prehospital LVO diagnosis offers the potential to transport patients directly to centers that have MT treatment available. In this study, we assess the accuracy of combining two biomarkers, HFABP and NT-proBNP, with clinical indicators to detect LVO using ultra-early prehospital blood samples. The study was registered in the German Clinical Trials Register (DRKS-ID: DRKS00030399).Methods and analysisWe plan a multicenter prospective observational study with 800 patients with suspected stroke enrolled within 24 h of symptom onset. Study participants will be recruited at three sites (MSUs) in Berlin, Germany. Blood-samples will be taken pre-hospitally at the scene and tested for HFABP and NT-proBNP levels. Additional clinical data and information on final diagnosis will be collected and documented in an electronic case report form (eCRF). Sensitivity and specificity of the combination will be calculated through iterative permutation-response calculations.DiscussionThis study aims to evaluate the diagnostic capabilities of a combination of the biomarkers HFABP and NT-proBNP in LVO prediction. In contrast to most other biomarker studies to date, by employing MSUs as study centers, ultra-early levels of biomarkers can be analyzed. Point-of-care LVO detection in suspected stroke could lead to faster treatment in both urban and rural settings and thus improve functional outcomes on a broader scale.Clinical trial registrationDeutsches Register klinischer Studien https://drks.de/search/de/trial/DRKS00030399, DRKS00030399

Keywords